Test Code PDEIS Phosphodiesterase 10A (PDE10A) IgG, Tissue Immunofluorescence, Serum
Specimen Required
Only orderable as part of a profile. For more information see:
ENS2 / Encephalopathy, Autoimmune/Paraneoplastic Evaluation, Serum
DMS2 / Dementia, Autoimmune/Paraneoplastic Evaluation, Serum
EPS2 / Epilepsy, Autoimmune/Paraneoplastic Evaluation, Serum
MDS2 / Movement Disorder, Autoimmune/Paraneoplastic Evaluation, Serum
Useful For
Detecting phosphodiesterase 10A (PDE10A)-IgG in serum specimens
Evaluation of autoimmune/paraneoplastic neurological syndromes among patients presenting with movement disorders and encephalopathy
Testing Algorithm
If the indirect immunofluorescence (IFA) pattern suggests phosphodiesterase 10A (PDE10A) IgG, then the PDE10A antibody IFA titer will be performed at an additional charge.
Method Name
Only orderable as part of a profile. For more information see:
ENS2 / Encephalopathy, Autoimmune/Paraneoplastic Evaluation, Serum
DMS2 / Dementia, Autoimmune/Paraneoplastic Evaluation, Serum
EPS2 / Epilepsy, Autoimmune/Paraneoplastic Evaluation, Serum
MDS2 / Movement Disorder, Autoimmune/Paraneoplastic Evaluation, Serum
Indirect Immunofluorescence Assay (IFA)
Reporting Name
PDE10A Ab IFA, SSpecimen Type
SerumSpecimen Minimum Volume
1 mL
Specimen Stability Information
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Serum | Refrigerated (preferred) | 28 days | |
Frozen | 28 days | ||
Ambient | 72 hours |
Reject Due To
Gross hemolysis | Reject |
Gross lipemia | Reject |
Gross icterus | Reject |
Clinical Information
Phosphodiesterase 10A (PDE10A) is a marker of paraneoplastic neurological autoimmunity in patients presenting with movement disorders, encephalopathy, and often, cancer.
Reference Values
Only orderable as part of a profile. For more information see:
ENS2 / Encephalopathy, Autoimmune/Paraneoplastic Evaluation, Serum
DMS2 / Dementia, Autoimmune/Paraneoplastic Evaluation, Serum
EPS2 / Epilepsy, Autoimmune/Paraneoplastic Evaluation, Serum
MDS2 / Movement Disorder, Autoimmune/Paraneoplastic Evaluation, Serum
Negative
Interpretation
A positive result is consistent with phosphodiesterase 10A (PDE10A) autoimmunity that manifests with autoimmune movement disorders or encephalitis. A paraneoplastic cause should be considered.
Cautions
A negative result does not exclude the presence of neurological autoimmunity or cancer. The use of immunosuppressive therapy prior to sample collection may negatively impact the sensitivity of this assay.
Method Description
The patient's sample is tested by a standardized immunofluorescence assay that uses a composite frozen section of mouse cerebellum, kidney, and gut tissues. After incubation with sample and washing, fluorescein-conjugated goat-antihuman IgG is applied. Neuron-specific autoantibodies are identified by their characteristic fluorescence staining patterns. Samples that are scored positive for any neuronal nuclear or cytoplasmic autoantibody are titrated to an endpoint. Interference by coexisting non-neuron-specific autoantibodies can usually be eliminated by serologic absorption.(Honorat JA, Komorowski L, Josephs KA, et al. IgLON5 antibody: neurological accompaniments and outcomes in 20 patients. Neurol Neuroimmunol Neuroinflamm. 2017;4[5]:e385. doi:10.1212/NXI.0000000000000385)
Day(s) Performed
Monday through Sunday
Report Available
5 to 10 daysSpecimen Retention Time
28 daysPerforming Laboratory
Mayo Clinic Laboratories in RochesterTest Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
86255
LOINC Code Information
Test ID | Test Order Name | Order LOINC Value |
---|---|---|
PDEIS | PDE10A Ab IFA, S | 103842-1 |
Result ID | Test Result Name | Result LOINC Value |
---|---|---|
620068 | PDE10A Ab IFA, S | 103842-1 |